[go: up one dir, main page]

AR092532A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents

Etanercept correctamente plegado de alta pureza y excelente rendimiento

Info

Publication number
AR092532A1
AR092532A1 ARP130103250A ARP130103250A AR092532A1 AR 092532 A1 AR092532 A1 AR 092532A1 AR P130103250 A ARP130103250 A AR P130103250A AR P130103250 A ARP130103250 A AR P130103250A AR 092532 A1 AR092532 A1 AR 092532A1
Authority
AR
Argentina
Prior art keywords
protein
folded
correctly folded
etanercept
mixed mode
Prior art date
Application number
ARP130103250A
Other languages
English (en)
Inventor
Arakawa Tsutomu
Farrar Douglas
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092532(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AR092532A1 publication Critical patent/AR092532A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/165Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La solicitud está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto. Reivindicación 1: Un método de cromatografía de modo mixto para separar una proteína correctamente plegada de una proteína incorrectamente plegada, que comprende los pasos de: (a) unir una primera mezcla de proteínas que comprende ambas conformaciones correctamente plegada e incorrectamente plegada de una proteína dada con una resina de cromatografía de modo mixto que tiene porciones de intercambio iónico y porciones hidrofóbicas; (b) eluir la proteína correctamente plegada de la resina de modo mixto para obtener una segunda mezcla de proteínas que Comprende una mayor proporción de proteína correctamente plegada que la primera mezcla de proteínas.
ARP130103250A 2012-09-11 2013-09-11 Etanercept correctamente plegado de alta pureza y excelente rendimiento AR092532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
AR092532A1 true AR092532A1 (es) 2015-04-22

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103250A AR092532A1 (es) 2012-09-11 2013-09-11 Etanercept correctamente plegado de alta pureza y excelente rendimiento

Country Status (33)

Country Link
US (6) US20140072560A1 (es)
EP (1) EP2895188B1 (es)
JP (3) JP2015533797A (es)
KR (2) KR102133699B1 (es)
CN (2) CN104902914B (es)
AR (1) AR092532A1 (es)
AU (2) AU2013315750B9 (es)
BR (1) BR112015005161A2 (es)
CA (1) CA2882551A1 (es)
CL (1) CL2015000572A1 (es)
CO (1) CO7400876A2 (es)
CY (1) CY1120062T1 (es)
DK (1) DK2895188T3 (es)
DO (1) DOP2015000055A (es)
EA (1) EA031324B1 (es)
EC (1) ECSP15014138A (es)
ES (1) ES2657377T3 (es)
HR (1) HRP20180182T1 (es)
HU (1) HUE036524T2 (es)
IL (2) IL237311B (es)
IN (1) IN2015KN00452A (es)
LT (1) LT2895188T (es)
MX (2) MX360044B (es)
NO (1) NO2972131T3 (es)
PE (2) PE20200607A1 (es)
PL (1) PL2895188T3 (es)
PT (1) PT2895188T (es)
RS (1) RS57013B1 (es)
SG (1) SG11201501460RA (es)
SI (1) SI2895188T1 (es)
SM (1) SMT201800163T1 (es)
TW (2) TWI609877B (es)
WO (1) WO2014043103A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
TWI595883B (zh) 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 用木糖醇穩定化之依那西普調配物
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
US10556942B2 (en) 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
MX2018005831A (es) * 2015-11-18 2018-08-01 Merck Patent Gmbh Gradientes de ph-sal opuestos para separaciones de proteina mejoradas.
KR20180083409A (ko) * 2015-11-18 2018-07-20 메르크 파텐트 게엠베하 이온 교환 크로마토그래피에서의 개선된 단백질 분리
PL3472177T3 (pl) * 2016-06-17 2024-11-25 F. Hoffmann-La Roche Ag Oczyszczanie przeciwciał wieloswoistych
KR102446838B1 (ko) * 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
JP7655610B2 (ja) * 2017-03-24 2025-04-02 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 組換え抗体断片の精製方法
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
US20230167153A1 (en) 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
JP2024510480A (ja) * 2021-03-16 2024-03-07 カシーヴ バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー 融合タンパク質の新規製剤
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AU2022369694B2 (en) * 2021-10-19 2025-10-09 Alteogen, Inc Method for purifying fusion protein having igg fc domain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
PT1478394E (pt) * 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US8937045B2 (en) 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
NZ545221A (en) 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
US7750129B2 (en) * 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CA2634547C (en) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
AU2009222115A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーAffibody Ab ポリペプチド
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
JP5791602B2 (ja) 2009-08-07 2015-10-07 イー・エム・デイー・ミリポア・コーポレイシヨン 試料中の1つ以上の不純物から標的タンパク質を精製するための方法
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
JP6347949B2 (ja) 2010-04-26 2018-06-27 ノバルティス アーゲー 改良型細胞培養培地
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
CN103379949B (zh) * 2010-10-11 2016-09-14 艾伯维巴哈马有限公司 蛋白纯化方法
AU2012244764B2 (en) 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013009526A1 (en) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
TWI595883B (zh) * 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 用木糖醇穩定化之依那西普調配物
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
WO2016015163A1 (en) * 2014-07-31 2016-02-04 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
PL2895188T3 (pl) 2018-06-29
CA2882551A1 (en) 2014-03-20
US20190300601A1 (en) 2019-10-03
CL2015000572A1 (es) 2016-02-05
ES2657377T3 (es) 2018-03-05
TW201803593A (zh) 2018-02-01
US20190330325A1 (en) 2019-10-31
US20140072560A1 (en) 2014-03-13
AU2018247244B2 (en) 2020-05-28
IL267452A (en) 2019-08-29
KR20150056601A (ko) 2015-05-26
IL237311B (en) 2019-07-31
HRP20180182T1 (hr) 2018-04-20
SI2895188T1 (en) 2018-05-31
RS57013B1 (sr) 2018-05-31
WO2014043103A1 (en) 2014-03-20
EP2895188A4 (en) 2016-05-25
JP2015533797A (ja) 2015-11-26
US10954294B2 (en) 2021-03-23
AU2013315750A1 (en) 2015-03-05
HUE036524T2 (hu) 2018-07-30
AU2018247244A1 (en) 2018-11-01
CN104902914B (zh) 2019-01-01
BR112015005161A2 (pt) 2017-07-04
JP6913066B2 (ja) 2021-08-04
CN104902914A (zh) 2015-09-09
US11001627B2 (en) 2021-05-11
PT2895188T (pt) 2018-02-08
JP2021100929A (ja) 2021-07-08
PE20150996A1 (es) 2015-08-01
AU2013315750B2 (en) 2018-07-12
DOP2015000055A (es) 2015-04-30
EA031324B1 (ru) 2018-12-28
DK2895188T3 (en) 2018-02-26
SMT201800163T1 (it) 2018-05-02
CO7400876A2 (es) 2015-09-30
MX360044B (es) 2018-10-19
MX2018012749A (es) 2020-11-12
SG11201501460RA (en) 2015-04-29
AU2013315750B9 (en) 2018-11-15
TWI609877B (zh) 2018-01-01
PE20200607A1 (es) 2020-03-10
ECSP15014138A (es) 2016-01-29
KR20200085937A (ko) 2020-07-15
CN110051823A (zh) 2019-07-26
EP2895188B1 (en) 2017-11-15
TWI716649B (zh) 2021-01-21
IL267452B (en) 2021-05-31
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (es) 2018-04-21
IN2015KN00452A (es) 2015-07-17
IL237311A0 (en) 2015-04-30
TW201425331A (zh) 2014-07-01
US20190300600A1 (en) 2019-10-03
LT2895188T (lt) 2018-04-10
EP2895188A1 (en) 2015-07-22
US10954293B2 (en) 2021-03-23
US20180037642A1 (en) 2018-02-08
EA201590542A1 (ru) 2015-07-30
US20190300602A1 (en) 2019-10-03
US10954295B2 (en) 2021-03-23
MX2015003090A (es) 2015-07-14
CY1120062T1 (el) 2018-12-12
US10947306B2 (en) 2021-03-16
KR102133699B1 (ko) 2020-07-14
JP2019038817A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
AR092532A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
WO2014141152A3 (en) Low concentration antibody formulations
CO2020001872A2 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CY1119576T1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
EA201892693A1 (ru) Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
PE20060816A1 (es) Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
EA201791350A9 (ru) Радиофармацевтические комплексы
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
MX2018013685A (es) Terapia de combinacion de cebadadura:refuerzo.
CO2023004265A2 (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
BR112012022292A2 (pt) método para produção da proteína recombinante interferon solúvel sem desnaturação.
HK1243329A1 (zh) 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途
김연숙 et al. High Performance Liquid Chromatography Analysis of Human Salivary Protein Complexes

Legal Events

Date Code Title Description
FC Refusal